A Vargas-Palacios1, D M Meads1, M Twiddy2, C Czoski Murray1, C Hulme1, E D Mitchell2, A Gregson3, P Stanley4, J Minton5. 1. Academic Unit of Health Economics, University of Leeds, Leeds, UK. 2. Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. 3. Leeds Community Healthcare Trust, Leeds, UK. 4. Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK. 5. Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Abstract
Objectives: In the UK, patients who require intravenous antimicrobial (IVA) treatment may receive this in the community through outpatient parenteral antimicrobial therapy (OPAT) services. Services include: IVA administration at a hospital outpatient clinic (HO); IVA administration at home by a general nurse (GN) or a specialist nurse (SN); or patient self-administered (SA) IVA administration following training. There is uncertainty regarding which OPAT services represent value for money; this study aimed to estimate their cost-effectiveness. Methods: A cost-effectiveness decision-analytic model was developed using a simulation technique utilizing data from hospital records and a systematic review of the literature. The model estimates cost per QALY gained from the National Health Service (NHS) perspective for short- and long-term treatment of infections and service combinations across these. Results: In short-term treatments, HO was estimated as the most effective (0.7239 QALYs), but at the highest cost (£973). SN was the least costly (£710), producing 0.7228 QALYs. The combination between SN and HO was estimated to produce 0.7235 QALYs at a cost of £841. For long-term treatments, SN was the most effective (0.677 QALYs), costing £2379, while SA was the least costly at £1883, producing 0.666 QALYs. A combination of SA and SN was estimated to produce 0.672 QALYs at a cost of £2128. Conclusions: SN and SA are cost-effective for short- and long-term treatment of infections, while combining services may represent the second-best alternative for OPAT in the UK.
Objectives: In the UK, patients who require intravenous antimicrobial (IVA) treatment may receive this in the community through outpatient parenteral antimicrobial therapy (OPAT) services. Services include: IVA administration at a hospital outpatient clinic (HO); IVA administration at home by a general nurse (GN) or a specialist nurse (SN); or patient self-administered (SA) IVA administration following training. There is uncertainty regarding which OPAT services represent value for money; this study aimed to estimate their cost-effectiveness. Methods: A cost-effectiveness decision-analytic model was developed using a simulation technique utilizing data from hospital records and a systematic review of the literature. The model estimates cost per QALY gained from the National Health Service (NHS) perspective for short- and long-term treatment of infections and service combinations across these. Results: In short-term treatments, HO was estimated as the most effective (0.7239 QALYs), but at the highest cost (£973). SN was the least costly (£710), producing 0.7228 QALYs. The combination between SN and HO was estimated to produce 0.7235 QALYs at a cost of £841. For long-term treatments, SN was the most effective (0.677 QALYs), costing £2379, while SA was the least costly at £1883, producing 0.666 QALYs. A combination of SA and SN was estimated to produce 0.672 QALYs at a cost of £2128. Conclusions: SN and SA are cost-effective for short- and long-term treatment of infections, while combining services may represent the second-best alternative for OPAT in the UK.
Authors: R Andrew Seaton; Victor J Gonzalez-Ramallo; Vincenzo Prisco; M Marcano-Lozada; A Gonzalez-Ruiz; B Gallegos; F Menichetti; J Loeffler; Kamel Bouylout; Ricardo L Chaves Journal: Int J Antimicrob Agents Date: 2013-03-06 Impact factor: 5.283
Authors: Philippa C Matthews; Christopher P Conlon; Anthony R Berendt; Jill Kayley; Lorrayne Jefferies; Bridget L Atkins; Ivor Byren Journal: J Antimicrob Chemother Date: 2007-06-11 Impact factor: 5.790
Authors: Jonathan Underwood; Michael Marks; Steve Collins; Sarah Logan; Gabriele Pollara Journal: J Antimicrob Chemother Date: 2019-03-01 Impact factor: 5.790